Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

The interest in HER2-low breast cancer (BC) has increased in recent years with the development of novel anti-HER2 antibody–drug conjugates. Here, we investigated the clinical outcomes and relapse patterns of patients with HER2-low or -zero BCs in an Asian population. We retrospectively identified HE...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2022-11, Vol.176, p.30-40
Main Authors: Kang, Sora, Lee, So H., Lee, Hee J., Jeong, Hyehyun, Jeong, Jae H., Kim, Jeong E., Ahn, Jin-Hee, Jung, Kyung H., Gong, Gyungyub, Kim, Hak H., Lee, Saebyeol, Lee, Jongwon, Kim, Sung-Bae
Format: Article
Language:English
Subjects:
Antibodies
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Chemotherapy
Chemotherapy, Adjuvant
ErbB-2 protein
Female
Health care facilities
HER2-low
HER2-zero
Humans
Neoadjuvant Therapy
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Pathological complete response
Patients
Prognosis
Receptor, ErbB-2
Retrospective Studies
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The interest in HER2-low breast cancer (BC) has increased in recent years with the development of novel anti-HER2 antibody–drug conjugates. Here, we investigated the clinical outcomes and relapse patterns of patients with HER2-low or -zero BCs in an Asian population. We retrospectively identified HER2-low or -zero BC patients with stage I–III tumours who were treated with neoadjuvant chemotherapy and underwent curative surgery, between 2014 and 2018 at Asan Medical Center, Seoul, Korea. A total of 818 and 754 HER2-zero and HER2-low BC patients, respectively, were consecutively included in this analysis. The HER2-low group had more hormone receptor [HR]-positive patients (81% versus 56%, P 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2022.08.031